Posts tagged as

Mark Atkinson

Diamyd Medical contributes to JDRF initiative to increase understanding of Type 1 diabetes

Diamyd Medical, a Swedish medical research company, annouced that it will join a research initiative launched by JDRF aimed at increasing the understanding of the natural progression of type 1 diabetes in order to transform and accelerate drug development for the disease. Diamyd Medical will contribute data that will be made available to industry and academia partners through an open access database together with similar data from other late stage type 1 diabetes studies.

UF Diabetes Institute Director, Researcher Honored by JDRF

Mark A. Atkinson, PhD., director of the University of Florida Diabetes Institute, and Alberto Pugliese, M.D., head of the Immunogenetics Program at the University of Miami's Diabetes Research Institute, were recently honored with the JDRF Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award on behalf of the JDRF Network for Pancreatic Organ Donors with Diabetes (nPOD). Learn more.

$1.5 million grant targets immune cell therapies in Type 1 diabetes

Benjamin Keselowsky, Ph.D. has received a new NIH R01 grant for “Biomaterial Delivery System for Type 1 Diabetes Vaccine”. Funded by the National Institute of Diabetes and Digestive and Kidney Diseases in collaboration with UF Diabetes Institute Director, Mark Atkinson, Ph.D., and Clive Wasserfall, this, $1.5M grant will fund the investigation of biodegradable microparticle/hydrogel formulations delivering immuno-modulatory factors to targeted immune cell types for the prevention and reversal of T1D.

Diabetes: A Global Burden

In 2013, the global prevalence of diabetes was estimated at 382 million. By 2035, the number is expected to reach 592 million. The International Diabetes Federation (IDF) estimates that 8.3% of adults – 382 million people – have diabetes, and the…

Bacteria in the Gut Offer Clues to Diabetes

A new study co-authored by University of Florida diabetes researchers finds that bacteria in the guts of young children with type 1 diabetes are different from those of other kids. The research is helping clarify the importance of healthy gut bacteria development in early childhood and could help lead to novel prevention therapies for people at risk of developing the disease.

UF Researchers Named Among Top 10 International Type 1 Diabetes Experts

UF Diabetes Institute co-directors Mark Atkinson, PhD and Desmond Schatz, MD, are recognized as global leading authorities in the field of Type 1 diabetes mellitus. Together, their preeminent research contributions are shedding light on promising new therapies to treat and prevent this disease. Learn more about this outstanding achievement.